HORSHOLM, Denmark, Nov. 20 (UPI) -- ALK-Abello said Monday it launched its tablet-based vaccine against grass pollen allergy, Grazax, in Germany.
"The launch of Grazax is the culmination of years of research and development at ALK-Abello," said Jens Bager, ALK-Abello's chief executive officer. "With this convenient tablet for home treatment, many more patients throughout Europe can be offered a treatment that targets the cause of their allergy, cuts the symptoms and improves their quality of life."
The company said it plans to introduce the vaccine in other, unspecified European markets.
Grazax, which is intended for once-daily home administration, should be started at least 8 weeks before the start of grass pollen season. In a clinical trial, 82 percent of patients treated with Grazax reported feeling "better" or "much better" compared with previous grass pollen seasons in which they did not receive the vaccine.
source - UPI